Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pegylated liposomal doxorubicin + ZN-c3 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pegylated liposomal doxorubicin | Doxil | ATI-0918|CAELYX|liposomal doxorubicin | Chemotherapy - Anthracycline 13 | Doxil (pegylated liposomal doxorubicin) comprises the anthracyline doxorubicin, which intercalates into DNA and disrupts DNA replication, encapsulated in a liposome, which improves tumor penetration and decreases toxicity (NCI Drug Dictionary), and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov). |
ZN-c3 | ZNc3|ZN c3|azenosertib | WEE1 Inhibitor 8 | ZN-c3 is a small molecular inhibitor of WEE1 and inhibition of WEE1 increases DNA damage in cancer cells to induce programmed cell death (J Clin Oncol 41, 2023 (suppl 16; abstr 5513)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04516447 | Phase I | Pegylated liposomal doxorubicin + ZN-c3 Carboplatin + ZN-c3 | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | BGR | AUS | 4 |